http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 18 Aug 2026 07:01:45 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Genprex+signs+CDMO+deal+to+scale+up+diabetes+gene+therapy+output/26940409.html <p>Genprex, Inc. (NASDAQ: GNPX) has entered into a development and manufacturing agreement with a U.S.-based contract development and manufacturing organization (CDMO) to scale up production of its diabetes gene therapy candidate, the company said in a press release dated Aug. 18, 2026.</p><p>The agreement moves the company's AAV-based therapy from research-grade production to a current Good Manufacturing Practices (cGMP) compliant facility. The CDMO will manufacture and supply drug product for IND-enabling preclinical studies and future clinical trials.</p><p>The manufacturing plan includes process optimization using AAV production technologies, scale-up via capacity bioreactors, analytical qualification and potency assay development, and cGMP compliance to support http://www.streetinsider.com/Corporate+News/Genprex+signs+CDMO+deal+to+scale+up+diabetes+gene+therapy+output/26940409.html Tue, 18 Aug 2026 07:01:45 -0400 GNPX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+18/26940411.html si-local-file:///var/storage/secattach/20260818/26940411.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+18/26940411.html Tue, 18 Aug 2026 07:01:00 -0400 GNPX O.21974237 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+18/26940411.html si-local-file:///var/storage/secattach/20260818/26940411.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+18/26940411.html Tue, 18 Aug 2026 07:01:00 -0400 GNPX O.21974237 http://www.streetinsider.com/Press+Releases/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html <div class="xn-content"> <p class="prntac"><i>Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4754148-1&amp;h=922557021&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading <location value="LC/us" idsrc="xmltag.org" >U.S</location>. based clinical and commercial <span>Contract Development and Manufacturing Organization</span> (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy http://www.streetinsider.com/Press+Releases/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html Tue, 18 Aug 2026 07:00:00 -0400 A.50208593 GNPX O.00303771 O.21974237 http://www.streetinsider.com/Press+Releases/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html <div class="xn-content"> <p class="prntac"><i>Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4754148-1&amp;h=922557021&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading <location value="LC/us" idsrc="xmltag.org" >U.S</location>. based clinical and commercial <span>Contract Development and Manufacturing Organization</span> (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy http://www.streetinsider.com/Press+Releases/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html Tue, 18 Aug 2026 07:00:00 -0400 A.50208593 GNPX O.00303771 O.21974237 http://www.streetinsider.com/Press+Releases/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html <div class="xn-content"> <p class="prntac"><i>Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4754148-1&amp;h=922557021&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading <location value="LC/us" idsrc="xmltag.org" >U.S</location>. based clinical and commercial <span>Contract Development and Manufacturing Organization</span> (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy http://www.streetinsider.com/Press+Releases/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html Tue, 18 Aug 2026 07:00:00 -0400 A.50208593 GNPX O.00303771 O.21974237 http://www.streetinsider.com/Press+Releases/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html <div class="xn-content"> <p class="prntac"><i>Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4754148-1&amp;h=922557021&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading <location value="LC/us" idsrc="xmltag.org" >U.S</location>. based clinical and commercial <span>Contract Development and Manufacturing Organization</span> (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy http://www.streetinsider.com/Press+Releases/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html Tue, 18 Aug 2026 07:00:00 -0400 A.50208593 GNPX O.00303771 O.21974237 http://www.streetinsider.com/PRNewswire/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html <div class="xn-content"> <p class="prntac"><i>Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4754148-1&amp;h=922557021&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading <location value="LC/us" idsrc="xmltag.org" >U.S</location>. based clinical and commercial <span>Contract Development and Manufacturing Organization</span> (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy http://www.streetinsider.com/PRNewswire/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html Tue, 18 Aug 2026 07:00:00 -0400 A.50208593 GNPX O.00303771 O.21974237 http://www.streetinsider.com/PRNewswire/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html <div class="xn-content"> <p class="prntac"><i>Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4754148-1&amp;h=922557021&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading <location value="LC/us" idsrc="xmltag.org" >U.S</location>. based clinical and commercial <span>Contract Development and Manufacturing Organization</span> (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy http://www.streetinsider.com/PRNewswire/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html Tue, 18 Aug 2026 07:00:00 -0400 A.50208593 GNPX O.00303771 O.21974237 http://www.streetinsider.com/PRNewswire/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html <div class="xn-content"> <p class="prntac"><i>Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4754148-1&amp;h=922557021&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading <location value="LC/us" idsrc="xmltag.org" >U.S</location>. based clinical and commercial <span>Contract Development and Manufacturing Organization</span> (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy http://www.streetinsider.com/PRNewswire/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html Tue, 18 Aug 2026 07:00:00 -0400 A.50208593 GNPX O.00303771 O.21974237 http://www.streetinsider.com/PRNewswire/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html <div class="xn-content"> <p class="prntac"><i>Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 18, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4754148-1&amp;h=922557021&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into a development and manufacturing agreement with a leading <location value="LC/us" idsrc="xmltag.org" >U.S</location>. based clinical and commercial <span>Contract Development and Manufacturing Organization</span> (CDMO) to initiate the manufacturing scale-up of its diabetes gene therapy http://www.streetinsider.com/PRNewswire/Genprex+Selects+Leading+Clinical+and+Commercial+Contract+Development+and+Manufacturing+Organization+for+Manufacturing+Scale+Up+of+Diabetes+Gene+Therapy/26940353.html Tue, 18 Aug 2026 07:00:00 -0400 A.50208593 GNPX O.00303771 O.21974237 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Genprex%2C+Inc.+++++++++++++For%3A+Jun+30/26925813.html si-local-file:///var/storage/secattach/20260814/26925813.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Genprex%2C+Inc.+++++++++++++For%3A+Jun+30/26925813.html Fri, 14 Aug 2026 09:28:00 -0400 GNPX O.21974237 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Genprex%2C+Inc.+++++++++++++For%3A+Jun+30/26925813.html si-local-file:///var/storage/secattach/20260814/26925813.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Genprex%2C+Inc.+++++++++++++For%3A+Jun+30/26925813.html Fri, 14 Aug 2026 09:28:00 -0400 GNPX O.21974237 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+04/26875093.html si-local-file:///var/storage/secattach/20260805/26875093.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+04/26875093.html Wed, 05 Aug 2026 16:32:00 -0400 GNPX O.21974237 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+04/26875093.html si-local-file:///var/storage/secattach/20260805/26875093.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+04/26875093.html Wed, 05 Aug 2026 16:32:00 -0400 GNPX O.21974237 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+03/26853743.html si-local-file:///var/storage/secattach/20260803/26853743.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+03/26853743.html Mon, 03 Aug 2026 07:02:00 -0400 GNPX O.21974237 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+03/26853743.html si-local-file:///var/storage/secattach/20260803/26853743.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Genprex%2C+Inc.+++++++++++++For%3A+Aug+03/26853743.html Mon, 03 Aug 2026 07:02:00 -0400 GNPX O.21974237 http://www.streetinsider.com/Corporate+News/Genprex+partners+with+Roche+Diagnostics+on+NSCLC+biomarker+studies/26853721.html <p>Genprex, Inc. (NASDAQ: GNPX) announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials, according to a press release dated Aug. 3, 2026.</p><p>The collaboration centers on TROP2 as a biomarker for identifying suitable patients for NSCLC clinical studies. Genprex's prior research indicated that high TROP2 H-scores and low PTEN H-scores were associated with patient response in preclinical studies. Clinical data showed longer Progression Free Survival in NSCLC patients with TROP2 H-scores above 100 and PTEN H-scores below 100.</p><p>Roche Diagnostics will perform assay validation using its TROP2 antibody, which is the http://www.streetinsider.com/Corporate+News/Genprex+partners+with+Roche+Diagnostics+on+NSCLC+biomarker+studies/26853721.html Mon, 03 Aug 2026 07:00:57 -0400 GNPX http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html <div class="xn-content"> <p class="prntac"><i>Collaboration Advances Biomarker-Driven Patient Selection and <span value="ACORN:5021701175" idsrc="xmltag.org" >Precision Medicine</span> in Oncology</i></p><p class="prntac"><i>Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=505564439&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=3463387034&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with <span value="ACORN:0880172493" idsrc="xmltag.org" >Roche Diagnostics</span> to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html Mon, 03 Aug 2026 07:00:00 -0400 A.06822034 A.08801724 A.50217011 GNPX O.00268852 O.20026344 O.21974237 O.76446908 http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html <div class="xn-content"> <p class="prntac"><i>Collaboration Advances Biomarker-Driven Patient Selection and <span value="ACORN:5021701175" idsrc="xmltag.org" >Precision Medicine</span> in Oncology</i></p><p class="prntac"><i>Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=505564439&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=3463387034&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with <span value="ACORN:0880172493" idsrc="xmltag.org" >Roche Diagnostics</span> to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html Mon, 03 Aug 2026 07:00:00 -0400 A.06822034 A.08801724 A.50217011 GNPX O.00268852 O.20026344 O.21974237 O.76446908 http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html <div class="xn-content"> <p class="prntac"><i>Collaboration Advances Biomarker-Driven Patient Selection and <span value="ACORN:5021701175" idsrc="xmltag.org" >Precision Medicine</span> in Oncology</i></p><p class="prntac"><i>Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=505564439&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=3463387034&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with <span value="ACORN:0880172493" idsrc="xmltag.org" >Roche Diagnostics</span> to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html Mon, 03 Aug 2026 07:00:00 -0400 A.06822034 A.08801724 A.50217011 GNPX O.00268852 O.20026344 O.21974237 O.76446908 http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html <div class="xn-content"> <p class="prntac"><i>Collaboration Advances Biomarker-Driven Patient Selection and <span value="ACORN:5021701175" idsrc="xmltag.org" >Precision Medicine</span> in Oncology</i></p><p class="prntac"><i>Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=505564439&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=3463387034&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with <span value="ACORN:0880172493" idsrc="xmltag.org" >Roche Diagnostics</span> to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html Mon, 03 Aug 2026 07:00:00 -0400 A.06822034 A.08801724 A.50217011 GNPX O.00268852 O.20026344 O.21974237 O.76446908 http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html <div class="xn-content"> <p class="prntac"><i>Collaboration Advances Biomarker-Driven Patient Selection and <span value="ACORN:5021701175" idsrc="xmltag.org" >Precision Medicine</span> in Oncology</i></p><p class="prntac"><i>Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=505564439&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=3463387034&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with <span value="ACORN:0880172493" idsrc="xmltag.org" >Roche Diagnostics</span> to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html Mon, 03 Aug 2026 07:00:00 -0400 A.06822034 A.08801724 A.50217011 GNPX O.00268852 O.20026344 O.21974237 O.76446908 http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html <div class="xn-content"> <p class="prntac"><i>Collaboration Advances Biomarker-Driven Patient Selection and <span value="ACORN:5021701175" idsrc="xmltag.org" >Precision Medicine</span> in Oncology</i></p><p class="prntac"><i>Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=505564439&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=3463387034&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with <span value="ACORN:0880172493" idsrc="xmltag.org" >Roche Diagnostics</span> to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html Mon, 03 Aug 2026 07:00:00 -0400 A.06822034 A.08801724 A.50217011 GNPX O.00268852 O.20026344 O.21974237 O.76446908 http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html <div class="xn-content"> <p class="prntac"><i>Collaboration Advances Biomarker-Driven Patient Selection and <span value="ACORN:5021701175" idsrc="xmltag.org" >Precision Medicine</span> in Oncology</i></p><p class="prntac"><i>Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.austin" idsrc="xmltag.org" >AUSTIN, Texas</location></span>, <span class="legendSpanClass"><chron>Aug. 3, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=505564439&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex, Inc.</span></a> ("<span value="NASDAQ-NMS:GNPX" idsrc="xmltag.org" >Genprex</span>" or the "Company") (NASDAQ: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4743394-1&amp;h=3463387034&amp;u=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2Fgnpx&amp;a=GNPX" target="_blank" rel="nofollow">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with <span value="ACORN:0880172493" idsrc="xmltag.org" >Roche Diagnostics</span> to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on http://www.streetinsider.com/Press+Releases/Genprex+Announces+Collaboration+with+Roche+Diagnostics+for+Biomarker+Assay+Validation+Studies/26853691.html Mon, 03 Aug 2026 07:00:00 -0400 A.06822034 A.08801724 A.50217011 GNPX O.00268852 O.20026344 O.21974237 O.76446908